Ignite Creation Date:
2024-05-06 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05031546
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2022-05-18
First Post:
2021-08-26
Brief Title:
Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin
Sponsor:
Cara Therapeutics Inc
Organization:
Cara Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Uremic Pruritus |
Keywords:
| Name | View |
|---|---|
| Hemodialysis | View |
| Pruritus | View |
| Uremic Pruritus | View |
| Dialysis | View |
| CR845 | View |
| Difelikefalin | View |
| Chronic Itch | View |
| CKD | View |
| CKD-associated pruritus | View |
| CKD-aP | View |
| ESRD end stage renal disease | View |
| Itch | View |
| Itching | View |
| KALM | View |
| Chronic Kidney Disease | View |
| Kidney failure chronic | View |
| Kidney dysfunction | View |
| Generalized pruritus | View |
| Expanded access | View |
| Compassionate use | View |